研究者詳細 - 田中　哲人

論文 - 田中　哲人

分割表示 211 件中 161 - 180 件目／全件表示 >>

Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions. 査読有り

Naganuma T, Kawamoto H, Panoulas VF, Latib A, Tanaka A, Mitomo S, Ruparelia N, Jabbour RJ, Chieffo A, Carlino M, Montorfano M, Colombo A

International journal of cardiology 246 巻頁： 26 - 31 2017年

Impact of Mitral Annular Calcium on Outcomes after Transcatheter Aortic Valve Implantation. 査読有り

Ancona MB, Giannini F, Mangieri A, Regazzoli D, Jabbour RJ, Tanaka A, Testa L, Romano V, Longoni M, Giglio M, Besana F, Cacucci M, Agricola E, Chieffo A, Alfieri O, Montorfano M, Colombo A, Latib A

The American journal of cardiology 120 巻 ( 12 ) 頁： 2233 - 2240 2017年

Tips and tricks for implanting BRSs: Sizing, pre- and postdilatation 査読有り

Tanaka, A., Jabbour, R.J., Colombo, A.

Bioresorbable Scaffolds: From Basic Concept to Clinical Applications 2017年

Clinical outcomes of a real-world cohort following bioresorbable vascular scaffold implantation utilising an optimised implantation strategy. 査読有り

Tanaka A, Latib A, Kawamoto H, Jabbour RJ, Sato K, Miyazaki T, Naganuma T, Mangieri A, Pagnesi M, Montalto C, Chieffo A, Carlino M, Montorfano M, Colombo A

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 12 巻 ( 14 ) 頁： 1730 - 1737 2016年10月

Bioresorbable Scaffolds: What Does "Less Forgiving" Mean? 査読有り

Tanaka A, Jabbour RJ, Latib A, Colombo A

JACC. Cardiovascular interventions 9 巻 ( 17 ) 頁： 1856 - 7 2016年9月

T-Stenting With Small Protrusion: The Default Strategy for Bailout Provisional Stenting? 査読有り

Jabbour RJ, Tanaka A, Pagnesi M, Regazzoli D, Mangieri A, Ancona M, Azzalini L, Giannini F, Montorfano M, Chieffo A, Carlino M, Latib A, Colombo A

JACC. Cardiovascular interventions 9 巻 ( 17 ) 頁： 1853 - 4 2016年9月

Minimal Acute Recoil Following Bioresorbable Scaffold Implantation in Fibrocalcific Lesion Detected by Optical Frequency-Domain Imaging. 査読有り

Kawamoto H, Ruparelia N, Tanaka A, Latib A, Colombo A

The Journal of invasive cardiology 28 巻 ( 3 ) 頁： E34 - 6 2016年3月

Case illustration of the difference between bench test and in-vivo scaffold fracture thresholds. 査読有り

Tanaka A, Jabbour RJ, Latib A, Colombo A

International journal of cardiology 225 巻頁： 20 - 22 2016年

Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease 査読有り

Ishii Hideki, Aoyama Toru, Takahashi Hiroshi, Kumada Yoshitaka, Kamoi Daisuke, Sakakibara Takashi, Umemoto Norio, Suzuki Susumu, Tanaka Akihito, Ito Yasuhiko, Murohara Toyoaki

JOURNAL OF CARDIOLOGY 67 巻 ( 2 ) 頁： 199 - 204 2016年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Journal of Cardiology

Background: Cilostazol has been reported to prevent atherosclerotic events in the general population. However, data have been limited whether there are beneficial effects of cilostazol use on long-term clinical outcomes after endovascular therapy in hemodialysis (HD) patients with peripheral artery disease (PAD). Methods and results: This study consisted of 595 HD patients undergoing endovascular therapy for a clinical diagnosis of PAD. They were divided into two groups: patients receiving 100. mg cilostazol twice daily in conjunction with standard therapy (n= 249 patients, cilostazol group) and those not administered cilostazol ( n= 346 patients, control group). A propensity score analysis was performed to adjust for baseline differences between the two groups. The propensity score-adjusted 10-year event-free survival rate from major adverse cardiovascular events (MACE) was significantly higher in the cilostazol group than in the control group [58.6% vs. 43.7%, hazard ratio (HR) 0.57; 95% confidence interval (CI) 0.41-0.79; p= 0.0010]. Notably, the adjusted stroke-free rate was significantly higher in the cilostazol group than in the control group (81.6% vs. 74.7%; HR = 0.48; 95% CI, 0.25-0.92, p= 0.028). Even after adjusting for other confounders, treatment with cilostazol was an independent predictor for prevention of MACE and stroke (p = 0.0028 and p= 0.039, respectively). Conclusions: Cilostazol administration improves long-term clinical outcomes including prevention of MACE and stroke after endovascular therapy in HD patients with PAD.

DOI： 10.1016/j.jjcc.2015.05.003

Progression from stenosis to occlusion in the proximal native coronary artery after coronary artery bypass grafting 査読有り

Tanaka Akihito, Ishii Hideki, Oshima Hideki, Shibata Yohei, Tatami Yosuke, Osugi Naohiro, Ota Tomoyuki, Kawamura Yoshihiro, Suzuki Susumu, Usui Akihiko, Murohara Toyoaki

HEART AND VESSELS 31 巻 ( 7 ) 頁： 1056 - 1060 2016年

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Heart and Vessels

Coronary artery bypass grafting (CABG) is an established treatment for multivessel coronary artery disease. However, problematic situations are occasionally encountered after CABG, such as disease progression in the native coronary artery with graft occlusion, which causes difficulty in revascularization. The purpose of this study was to evaluate changes in the native coronary artery after CABG. Between 2009 and 2012 in our institution, 351 patients underwent CABG, and 768 bypass grafts were anastomosed to non-occluded coronary arteries. Of these, 489 bypass grafts had available early postoperative angiographic results (≤6 months) suitable for assessment in this study. We defined malignant graft failure after CABG to be bypass graft occlusion and de novo complete occlusion of the target native coronary artery proximal to the graft anastomosis site. In the early angiographic results, 17 grafts were occluded (17/489; 3.5 %). Two of the grafts displayed malignant graft failure (a saphenous vein graft to the right coronary artery and a saphenous vein graft to the diagonal branch) (2 of 17 occluded grafts, and 2 of 489 studied grafts). Of the patent bypass grafts, 24 involved progression to occlusion in the proximal native coronary artery (19 saphenous vein grafts, 4 left internal thoracic artery grafts, and 1 right internal thoracic artery graft). Malignant graft failure was uncommon during short-term follow-up after CABG. At the same time, disease progression in the proximal native coronary artery from stenosis to occlusion following patent bypass grafting was relatively common, especially for vein grafts.

DOI： 10.1007/s00380-015-0715-8

Unfractionated Heparin during the Interruption of Antiplatelet Therapy for Non-cardiac Surgery after Drug-eluting Stent Implantation 査読有り

Tanaka Akihito, Ishii Hideki, Tatami Yosuke, Shibata Yohei, Osugi Naohiro, Ota Tomoyuki, Kawamura Yoshihiro, Suzuki Susumu, Nagao Yoshimasa, Matsushita Tadashi, Murohara Toyoaki

Internal Medicine 55 巻 ( 4 ) 頁： 333 - 337 2016年

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：一般社団法人日本内科学会

Objective Heparin is not recommended to be administered during the interruption of antiplatelet therapy for non-cardiac surgery. However, there are insufficient data to determine the value. The purpose of the present study was to evaluate the clinical results of the administration of unfractionated heparin during the interruption of antiplatelet therapy in non-cardiac surgery patients who had previously undergone drug-eluting stent (DES) implantation. Methods We retrospectively identified 210 elective non-cardiac surgical procedures that were performed with the administration of unfractionated heparin during interruption of all antiplatelet therapies in patients who had previously undergone DES implantation. Heparin was administered during the perioperative period in accordance with the local practice guideline at out institution. We examined the clinical outcomes within 30 days of surgery. Results The mean number of implanted DESs was 2.1±1.3. No major adverse cardiac events (including cardiac death, definite stent thrombosis, and non-fatal myocardial infarction) occurred in any of the 210 cases within 30 days of surgery. Four of the 210 cases (1.9%) required reoperation for bleeding within 30 days of surgery. Conclusion Our data showed the potential for the perioperative management with unfractionated heparin administration in Japanese patients who had previously undergone DES implantation who required non-cardiac surgery with the interruption of all antiplatelet therapies.

DOI： 10.2169/internalmedicine.55.5495

Reverse association of omega-3/omega-6 polyunsaturated fatty acids ratios with carotid atherosclerosis in patients on hemodialysis 査読有り

Umemoto Norio, Ishii Hideki, Kamoi Daisuke, Aoyama Toru, Sakakibara Takashi, Takahashi Hiroshi, Tanaka Akihito, Yasuda Yoshinari, Suzuki Susumu, Matsubara Tatsuaki, Murohara Toyoaki

ATHEROSCLEROSIS 249 巻頁： 65 - 69 2016年

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Atherosclerosis

Background and aims: Omega-3 (n-3) polyunsaturated fatty acids (PUFAs) are widely recognized to have beneficial effects against cardiovascular disease. We investigated the association of n-3 PUFAs levels with carotid atherosclerosis in patients on hemodialysis (HD), who are at high risk for cardiovascular events. Methods: Carotid ultra-sound was performed in a total of 461 patients on HD (male 67%, age 67 ± 12years, diabetes rate 46%). Intima-media thickness (IMT) and the plaque score (PS) in carotid arteries were measured. Carotid atherosclerosis was defined as IMT >1.2 mm and/or PS > 5.0. The levels of n-6 PUFAs [dihomo-gamma-linolenic acid (DHLA) and arachidonic acid (AA)] and n-3 PUFAs [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] were also measured prior to carotid ultra-sound. Results: Carotid atherosclerosis was observed in 94 patients (20.4%). Individual PUFAs levels were comparable between patients with and without carotid atherosclerosis. However, the ratio of EPA/AA and that of n-3/n-6 PUFAs were significantly lower in patients with carotid atherosclerosis compared to those without (median 0.36 vs. 0.41, p = 0.031 and 0.85 vs. 0.93, p = 0.041, respectively]. After adjustment for other confounders, the ratio of EPA/AA (OR 0.30, 95% CI 0.12-0.70, p = 0.0055) and the ratio of n-3/n-6 PUFAs (OR 0.45, 95% CI 0.25-0.80, p = 0.0066) showed an independent reverse association with carotid atherosclerosis. In addition, the area under receiver-operating characteristic curves for carotid atherosclerosis was significantly greater in an established risk model with EPA/AA and n-3/n-6 ratios than in the established risk model alone. Conclusions: These data suggest that low ratios of both EPA/AA ratio and n-3/n-6 PUFAs were closely associated with carotid atherosclerosis in patients on HD.

DOI： 10.1016/j.atherosclerosis.2016.03.037

Restored Physiological Vasomotion Imitating Intrascaffold Restenosis 3 Years After Bioresorbable Scaffold Implantation. 査読有り

Ancona MB, Tanaka A, Latib A, Jabbour RJ, Kawamoto H, Regazzoli D, Mangieri A, Colombo A

The Canadian journal of cardiology 32 巻 ( 12 ) 頁： 1574.e9 - 1574.e10 2016年

Preliminary Report of Clinical Outcomes After Single Crossover Bioresorbable Scaffold Implantation Without Routine Side Branch Strut Dilation. 査読有り

Tanaka A, Jabbour RJ, Kawamoto H, Mangieri A, Pagnesi M, Montalto C, Chieffo A, Carlino M, Montorfano M, Latib A, Colombo A

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 88 巻 ( 6 ) 頁： 865 - 870 2016年

Left main "Culotte in Culotte" to manage a trapped broken balloon. 査読有り

Ancona MB, Giannini F, Jabbour RJ, Tanaka A, Regazzoli D, Mangieri A, Carlino M, Colombo A

International journal of cardiology 221 巻頁： 347 - 9 2016年

Impact of post-procedural hyperglycemia on acute kidney injury after transcatheter aortic valve implantation. 査読有り

Giannini F, Latib A, Jabbour RJ, Ruparelia N, Aurelio A, Ancona MB, Figini F, Mangieri A, Regazzoli D, Tanaka A, Montalto C, Azzalini L, Monaco F, Agricola E, Chieffo A, Montorfano M, Alfieri O, Colombo A

International journal of cardiology 221 巻頁： 892 - 7 2016年

Incidence and significance of side branch occlusions following bioresorbable scaffold implantation for long left anterior descending artery lesions. 査読有り

Tanaka A, Jabbour RJ, Kawamoto H, Chieffo A, Carlino M, Montorfano M, Latib A, Colombo A

International journal of cardiology 222 巻頁： 674 - 675 2016年

Impact of Angiographic Result After Predilatation on Outcome After Drug-Coated Balloon Treatment of In-Stent Coronary Restenosis. 査読有り

Tanaka A, Latib A, Jabbour RJ, Kawamoto H, Giannini F, Ancona M, Regazzoli D, Mangieri A, Mattioli R, Chieffo A, Carlino M, Montorfano M, Colombo A

The American journal of cardiology 118 巻 ( 10 ) 頁： 1460 - 1465 2016年

Bioresorbable Scaffolds for the Management of Coronary Bifurcation Lesions. 査読有り

Kawamoto H, Ruparelia N, Tanaka A, Chieffo A, Latib A, Colombo A

JACC. Cardiovascular interventions 9 巻 ( 10 ) 頁： 989 - 1000 2016年

Multimodality evaluation of percutaneous closure of coronary fistula using AMPLATZER Vascular Plug IV. 査読有り

Regazzoli D, Giglio M, Besana F, Leone PP, Tanaka A, Ancona MB, Mangieri A, Montorfano M, Giannini F, De Angelis G, Colombo A, Latib A

International journal of cardiology 225 巻頁： 381 - 383 2016年

　前のページ - 次のページ　

<田中 哲人>

論文 - 田中 哲人

<田中　哲人>

論文 - 田中　哲人